Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Deloitte
US Army
Novartis
Accenture
Cantor Fitzgerald
Colorcon
Teva
McKinsey
Johnson and Johnson

Generated: January 17, 2018

DrugPatentWatch Database Preview

PHENTOLAMINE MESYLATE - Generic Drug Details

« Back to Dashboard

What are the generic sources for phentolamine mesylate and what is the scope of phentolamine mesylate patent protection?

Phentolamine mesylate
is the generic ingredient in three branded drugs marketed by Septodont Holding, Precision Dose Inc, West-ward Pharms Int, and Novartis, and is included in four NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Phentolamine mesylate has thirty-three patent family members in twenty countries.

There are four drug master file entries for phentolamine mesylate. Three suppliers are listed for this compound.
Summary for PHENTOLAMINE MESYLATE
Pharmacology for PHENTOLAMINE MESYLATE
Medical Subject Heading (MeSH) Categories for PHENTOLAMINE MESYLATE

US Patents and Regulatory Information for PHENTOLAMINE MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis REGITINE phentolamine mesylate INJECTABLE;INJECTION 008278-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Precision Dose Inc PHENTOLAMINE MESYLATE phentolamine mesylate INJECTABLE;INJECTION 207686-001 Jul 14, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
West-ward Pharms Int PHENTOLAMINE MESYLATE phentolamine mesylate INJECTABLE;INJECTION 040235-001 Mar 11, 1998 AP RX No Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for PHENTOLAMINE MESYLATE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,401 Local anesthetic methods and kits ➤ Subscribe
7,261,889 Local anesthetic methods and kits ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for PHENTOLAMINE MESYLATE

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chubb
Covington
Chinese Patent Office
Baxter
Colorcon
Fish and Richardson
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot